Last reviewed · How we verify
NCT07318597: ILLUMINATE
Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Phase 2 trial testing REGN13335 in Pulmonary Arterial Hypertension (PAH) in 99 participants. Not yet recruiting.
11 January 2028
Quick facts
| Lead sponsor | Regeneron Pharmaceuticals |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 99 |
| Start date | 29 January 2026 |
| Primary completion | 11 January 2028 |
| Estimated completion | 1 August 2028 |
Drugs / interventions tested
- REGN13335 — full drug profile →
- Placebo
Conditions studied
- Pulmonary Arterial Hypertension (PAH) — all drugs for Pulmonary Arterial Hypertension (PAH) →
Sponsor
Regeneron Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Pulmonary Arterial Hypertension (PAH). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07318597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of REGN13335
Trials testing the same drug.
- NCT06137482 — A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutane · Phase 1 · completed
Other recruiting trials for Pulmonary Arterial Hypertension (PAH)
Currently open trials in the same condition.
- NCT07245680 — COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities · Phase 3 · recruiting
- NCT06872112 — A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension · Phase 1 · recruiting
- NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
- NCT07457762 — AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? · NA · recruiting
- NCT06941441 — PAH Exercise Study · Phase 3 · recruiting
Other Regeneron Pharmaceuticals trials
Trials by the same sponsor.
- NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
- NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
- NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
- NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
- NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07318597 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
- Last refreshed: 6 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07318597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing